MA44777A - Anticorps humanisés anti-basigine et leur utilisation - Google Patents

Anticorps humanisés anti-basigine et leur utilisation

Info

Publication number
MA44777A
MA44777A MA044777A MA44777A MA44777A MA 44777 A MA44777 A MA 44777A MA 044777 A MA044777 A MA 044777A MA 44777 A MA44777 A MA 44777A MA 44777 A MA44777 A MA 44777A
Authority
MA
Morocco
Prior art keywords
humanized anti
basigin antibodies
basigin
antibodies
humanized
Prior art date
Application number
MA044777A
Other languages
English (en)
Inventor
Huijie Bian
Zhinan Chen
Wan Huang
Jianli Jiang
Mengyao Zhang
Yang Zhang
Zheng Zhang
Ping Zhu
Original Assignee
Fourth Military Medical Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical Univ filed Critical Fourth Military Medical Univ
Publication of MA44777A publication Critical patent/MA44777A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044777A 2016-04-29 2017-05-02 Anticorps humanisés anti-basigine et leur utilisation MA44777A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610285139.4A CN105820250B (zh) 2016-04-29 2016-04-29 一种抗basigin人源化抗体及其应用

Publications (1)

Publication Number Publication Date
MA44777A true MA44777A (fr) 2019-03-06

Family

ID=56528099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044777A MA44777A (fr) 2016-04-29 2017-05-02 Anticorps humanisés anti-basigine et leur utilisation

Country Status (25)

Country Link
US (2) US12240901B2 (fr)
EP (1) EP3448892A4 (fr)
JP (2) JP7099709B2 (fr)
KR (1) KR102369118B1 (fr)
CN (2) CN105820250B (fr)
AU (1) AU2017255888B2 (fr)
CA (1) CA3022308A1 (fr)
CL (1) CL2018003072A1 (fr)
CO (1) CO2018011663A2 (fr)
CR (1) CR20180515A (fr)
CU (1) CU24556B1 (fr)
DO (1) DOP2018000234A (fr)
EC (1) ECSP18084153A (fr)
IL (1) IL262588B2 (fr)
MA (1) MA44777A (fr)
MX (1) MX2018013176A (fr)
MY (1) MY196874A (fr)
NI (1) NI201800113A (fr)
PE (1) PE20190415A1 (fr)
PH (1) PH12018502293B1 (fr)
RU (1) RU2755150C2 (fr)
SG (1) SG11201809473QA (fr)
TN (1) TN2018000358A1 (fr)
WO (1) WO2017186182A1 (fr)
ZA (1) ZA201807132B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820250B (zh) 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
CN111690062B (zh) * 2019-03-14 2024-07-16 复旦大学 针对恶性疟PfRh5靶点的全人源单克隆抗体及应用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN113549152B (zh) * 2021-07-22 2023-06-20 中国人民解放军空军军医大学 一种抗basigin人源化抗体及其应用
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
CN119775410B (zh) * 2025-03-11 2025-04-29 成都大熊猫繁育研究基地 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0990031B1 (fr) * 1997-01-14 2006-03-29 Human Genome Sciences, Inc. Recepteur 5 du facteur de necrose tumorale
IL154751A0 (en) * 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US20050214302A1 (en) * 2004-03-25 2005-09-29 Marian Nakada Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
WO2008070344A2 (fr) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions et procédés permettant une liaison sphingosine-1-phosphate
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
KR20150126724A (ko) * 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2303325A4 (fr) * 2008-05-23 2012-09-19 Uti Limited Partnership Inhibition d'emmprin pour traiter la sclérose en plaques
WO2010087743A2 (fr) * 2008-12-30 2010-08-05 Cellartis Ab Utilisation d'une protéine dans une cellule souche et applications au cancer
ES2677564T3 (es) * 2009-06-19 2018-08-03 Inserm (Institut National De La Santé Et De La Recherche Medicale) Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
DK2510010T3 (en) * 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
WO2011112566A2 (fr) * 2010-03-11 2011-09-15 Abbott Laboratories Protéines de liaison de basigine
CN104086654B (zh) * 2014-07-04 2016-06-08 中国人民解放军第四军医大学 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
JP2020511130A (ja) * 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法

Also Published As

Publication number Publication date
AU2017255888A1 (en) 2018-11-22
CU20180129A7 (es) 2019-06-04
MY196874A (en) 2023-05-08
EP3448892A1 (fr) 2019-03-06
AU2017255888B2 (en) 2021-01-07
CU24556B1 (es) 2021-12-08
CO2018011663A2 (es) 2019-02-08
PH12018502293A1 (en) 2019-07-08
PE20190415A1 (es) 2019-03-19
TN2018000358A1 (en) 2020-06-15
KR20190020660A (ko) 2019-03-04
CN109476760B (zh) 2021-11-12
PH12018502293B1 (en) 2024-02-02
WO2017186182A1 (fr) 2017-11-02
CN105820250B (zh) 2019-04-30
RU2018138053A (ru) 2020-05-29
SG11201809473QA (en) 2018-11-29
KR102369118B1 (ko) 2022-03-03
NI201800113A (es) 2020-01-06
IL262588B1 (en) 2024-07-01
JP2022084832A (ja) 2022-06-07
US12240901B2 (en) 2025-03-04
CA3022308A1 (fr) 2017-11-02
BR112018072140A2 (pt) 2019-02-12
DOP2018000234A (es) 2018-10-31
CN109476760A (zh) 2019-03-15
MX2018013176A (es) 2019-06-24
ZA201807132B (en) 2021-05-26
US20250243273A1 (en) 2025-07-31
IL262588B2 (en) 2024-11-01
CR20180515A (es) 2019-05-15
JP2019521648A (ja) 2019-08-08
EP3448892A4 (fr) 2019-10-16
CN105820250A (zh) 2016-08-03
US20190270809A1 (en) 2019-09-05
IL262588A (en) 2018-12-31
RU2755150C2 (ru) 2021-09-13
RU2018138053A3 (fr) 2020-08-21
ECSP18084153A (es) 2019-03-29
JP7099709B2 (ja) 2022-07-12
CL2018003072A1 (es) 2019-05-31

Similar Documents

Publication Publication Date Title
IL262095A (en) Anti-pacap antibodies and uses thereof
EP3575318A4 (fr) Anticorps anti-pd-1 et son utilisation
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3604338A4 (fr) Anticorps anti-ox40 et utilisation correspondante
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA49034A (fr) Anticorps anti-lag3
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA47694A (fr) Anticorps anti-tigit
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3498840A4 (fr) Anticorps anti-lag-3
EP3473649A4 (fr) Anticorps monoclonal anti-cd47 et application correspondante
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
MA47268A (fr) Anticorps anti-gpc3
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
EP3423089A4 (fr) Anticorps anti-tigit
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA52285A (fr) Anticorps multispécifiques et leur utilisation
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
EP3612565A4 (fr) Anticorps anti-pd-l1 de et son utilisation
EP3503920A4 (fr) Anticorps anti-ctla4
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3448892A4 (fr) Anticorps humanisés anti-basigine et leur utilisation
EP3733705A4 (fr) Anticorps monoclonaux et procédés de leur utilisation